Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE
RESEARCH TOOLSreports
Sensei Biotherapeutics (SNSE) Stock Price & Analysis
167 Followers
SNSE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.51 - $1.94
Previous Close$0.72
Volume16.56K
Average Volume (3M)241.42K
Market Cap
$18.18M
Enterprise Value-$34.26M
Total Cash (Recent Filing)$58.08M
Total Debt (Recent Filing)$5.64M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 01, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding25,080,958
10 Day Avg. Volume78,570
30 Day Avg. Volume241,417
Standard Deviation0.16
R-Squared0.00023
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.28
Price to Sales (P/S)59.88
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-92.60
Enterprise Value/Gross Profit-103.51
Enterprise Value/Ebitda139.27
Forecast
1Y Price Target
$4.33Price Target Upside503.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Sensei Biotherapeutics News
PremiumCompany Announcements
Dr. Jessie English Resigns from Sensei Biotherapeutics Board
PremiumCompany Announcements
Sensei Biotherapeutics Unveils Updated Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSNS-101 demonstrated a tolerable safety profile, with only two cases of Gr1 CRS that were managed without steroids/tocilizumab.
Financial StabilityStrong balance sheet and cash runway support a path towards funding advanced clinical development programs.
Market PotentialSNS-101 could potentially be the first anti-VISTA mAb approved as a therapeutic agent.
Bears Say
Clinical TrialsData from Phase 1 dose escalation study of SNS-101 not as compelling as expected.
Earnings1Q24 EPS of ($0.32), compared to analyst's estimate of ($0.31).
Stock PerformanceThe stock is down significantly following the release of the ASCO abstract.
---
Ownership Overview
31.97% Insiders
3.30% Mutual Funds
6.61% Other Institutional Investors
58.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SNSE FAQ
What was Sensei Biotherapeutics’s price range in the past 12 months?
Sensei Biotherapeutics lowest stock price was $0.51 and its highest was $1.94 in the past 12 months.
What is Sensei Biotherapeutics’s market cap?
Currently, no data Available
When is Sensei Biotherapeutics’s upcoming earnings report date?
Sensei Biotherapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 11 days.
How were Sensei Biotherapeutics’s earnings last quarter?
Sensei Biotherapeutics released its earnings results on May 09, 2024. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.275 by -$0.045.
Is Sensei Biotherapeutics overvalued?
According to Wall Street analysts Sensei Biotherapeutics’s price is currently Undervalued.
Does Sensei Biotherapeutics pay dividends?
Sensei Biotherapeutics does not currently pay dividends.
What is Sensei Biotherapeutics’s EPS estimate?
Sensei Biotherapeutics’s EPS estimate is -$0.29.
How many shares outstanding does Sensei Biotherapeutics have?
Sensei Biotherapeutics has 25,080,957 shares outstanding.
What happened to Sensei Biotherapeutics’s price movement after its last earnings report?
Sensei Biotherapeutics reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.275. Following the earnings report the stock price went down -14.674%.
Which hedge fund is a major shareholder of Sensei Biotherapeutics?
Among the largest hedge funds holding Sensei Biotherapeutics’s share is Duquesne Family Office LLC. It holds Sensei Biotherapeutics’s shares valued at N/A.
---
Sensei Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (503.53% Upside)
$4.33 (503.53% Upside)
Hedge Fund Trend
Decreased
By 100.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.53%
12-Months-Change
Fundamentals
Return on Equity
-41.63%
Trailing 12-Months
Asset Growth
-38.21%
Trailing 12-Months
Company Description
Sensei Biotherapeutics
Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The companies ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.
---
SNSE Stock 12 Month Forecast
Average Price Target
$4.33
▲(503.53% Upside)
Technical Analysis
Sorrento Therapeutics
―
Arbutus Biopharma
―
Crinetics Pharmaceuticals
―
Arvinas Holding Company
―
Best Analysts Covering SNSE
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-16.57%
reiterated a buy rating 2 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -16.57% per trade.
---